Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 3/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250513 | 0.81 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL28722248 | 0.80 | OPRM1 (0.39) | MEN1KMT2A | |
| SCHEMBL316146 | 0.79 | THRB (0.32) | THRBTDP1AKR1C1 | |
| Hydrochloric Acid SCHEMBL2219432 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL21328421 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL28256376 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL1119645 | 0.78 | THRB (0.35) | THRBTDP1AKR1C1 | |
| SCHEMBL2121108 | 0.78 | SRR (0.32) | THRBTDP1AKR1C1 | |
| Hydrochloric Acid SCHEMBL8006256 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL6843337 | 0.78 | FFAR1 (0.34) | MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-108884058-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| CN-101272789-A | Melanocortin receptor-specific piperazine and ketone-piperazine compounds | PALATIN TECHNOLOGIES INC (US) | 2008-09-24 | — | — | CN | disclosed |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | MEN1 1568/4885KMT2A 1789/4885THRB 2733/4885 |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | MEN1 4778/4885KMT2A 820/4885THRB 367/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | MEN1 4751/4885KMT2A 2727/4885THRB 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.